BR

DRUG3 trials

Sponsors

AbbVie (prior sponsor, Abbott), Gilead Sciences, AstraZeneca

Conditions

Acquired Immune Deficiency Syndrome (AIDS)Chronic Lymphocytic LeukemiaHIV InfectionsUntreated Follicular Lymphoma

Phase 1

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

CompletedNCT00868413

AbbVie (prior sponsor, Abbott)Chronic Lymphocytic Leukemia

Start: 2009-11-30End: 2013-05-31Updated: 2013-06-07

Phase 2

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Active, not recruitingNCT02016924

Gilead SciencesAcquired Immune Deficiency Syndrome (AIDS), HIV Infections

Start: 2014-01-16End: 2027-03-01Updated: 2026-03-20

Phase 3

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

RecruitingNCT06549595

AstraZenecaUntreated Follicular Lymphoma

Start: 2024-08-07End: 2031-11-26Target: 1018Updated: 2026-03-18

Related Papers

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Blood2025-11-03

SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Blood2025-11-03

Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development.

2022-05-1914 citations

Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged<b>≥</b>3 to <12 Years

CPT Pharmacometrics & Systems Pharmacology2015-06-1912 citations